x

Like our Facebook Page

   
Early Times Newspaper Jammu, Leading Newspaper Jammu
 
Breaking News :   Jammu police held police-public meeting at Miran Sahib | Notorious criminals from Kashmir valley apprehended by Nowabad police | SSP Ramban chairs security review meet at DPO Ramban | Kishtwar police solves two theft cases | Jammu police booked notorious drug peddler of RS Pura area under PIT-NDPS Act | Two arrested for illegal transportation of bovine animals | Samba police foiled two bovine smuggling bids | Samba police reunites missing girl with family | Jammu police recovers 35 missing mobile phones in City North Zone | Bovine smuggling attempt foiled | Crack down on illegal mining continue, Samba police seizes 3 more vehicles | Poonch police traced out missing lady re-united with her family | Local industry pivotal in boosting economy, employment generation: Dy CM | Dr Darakhshan chairs Meraj-e-Aalam preparatory meeting | DIG Udhampur-Reasi range conducted Crime & OPS review meeting | Apex Court dismisses Govt's plea against HC direction to create 334 judicial posts | CJM rejects bail of PDD employee who fired on Advocate | Rupee drops 21 paise to 86.61 against US dollar | No reason to stay: Cong leaders question alliance with NC | Congress plans to make six leaders “scapegoats” to protect Tara Chand | Jammu: American Oncology Institute ‘exploiting’ poor, allege patients | PM Modi’s stellar start to 2025: Transforming vision into reality in just 15 days | Toxins found in samples, Police form SIT for investigation | Committed to strengthen JKRLM’s Umeed programme: CM Omar | Govt gives nod to setting up of 8th Pay Commission | Sonbhadra to emerge as a ‘green energy hub’ with floating solar power: CM Yogi | Urban Planning | CUJ, ISRO Centre launch eleventh radiosonde for atmospheric data collection | Red Ribbon Club hosts seminar on Health, Hygiene | MSc Biotechnology student from CUJ participates in Molecular Biology Workshop | Symposium on Save Girl Child, Save the Nation held | 30-hour GST Return Filing Course Commences at MCM | Lohri celebrated with enthusiasm at Desh Bhagat Global School | GDC Thannamandi felicitates NCC Cadets, celebrates National Start-up Day | Valedictory function of NSS winter camp held | Allen Scholarship Admission Test on January 19 | Back Issues  
 
news details
Good News: CSIR-IIIM Jammu’s research proves ‘Niclosamide’ is effective to treat COVID
6/7/2021 12:11:22 AM

Early Times Report

Jammu, June 6: When the whole world is desperately looking for an effective medicine to treat deadly Coronavirus, the Jammu branch of the Council of Scientific and Industrial Research-Indian Institute of Integrative Research (CSIR-IIIM) has recently demonstrated that the ‘Niclosamide’ is effective for the treatment of COVID. It was only after this research that CSIR India in collaboration with Laxai Life Sciences Pvt. Ltd has initiated phase-II clinical trial of this drug. Collaborative research between CSIR-IIIM, Jammu and National Centre for Biological Science (NCBS), Bangalore has recently demonstrated that Niclosamide is also a potential SARS-CoV2 entry inhibitor blocking the viral entry through pH-dependent endocytic pathway.
Niclosamide has been extensively used in past for the treatment of tapeworm’s infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels.
As per an official handout issued by the ministry of science and technology, in a screen to identify drugs that can inhibit syncytia formation, Niclosamide was identified as a promising repurposed drug by a research group from King’s College, London, who collaborated in this project. The syncytia or fused cells observed in the lungs of patients with COVID probably results from the fusogenic activity of the SARS-CoV-2 spike protein and Niclosamide can inhibit syncytia formation.
Dr Shekhar C Mande, Director General, CSIR expressed his happiness over the SEC recommendations to conduct this phase II clinical trial using Niclosamide, which is generic, affordable drug and easily available in India and therefore can be made available to our population.
Realizing the potential of Niclosamide, efforts were initiated last year itself to undertake clinical trials. Having received approval from drug regulator, the clinical trial has been initiated this week at different sites and is expected that the trial will be completed within 8-12 weeks. Based on successful clinical evidence generated during clinical trials in Indian studies, emergency use authorization may be sought so that more treatment options are available to COVID patients.
  Share This News with Your Friends on Social Network  
  Comment on this Story  
 
 
 
Early Times Android App
STOCK UPDATE
  
BSE Sensex
NSE Nifty
 
CRICKET UPDATE
 
 
 
 
 
 
 
 
   
Home About Us Top Stories Local News National News Sports News Opinion Editorial ET Cetra Advertise with Us ET E-paper
 
 
J&K RELATED WEBSITES
J&K Govt. Official website
Jammu Kashmir Tourism
JKTDC
Mata Vaishnodevi Shrine Board
Shri Amarnath Ji Shrine Board
Shri Shiv Khori Shrine Board
UTILITY
Train Enquiry
IRCTC
Matavaishnodevi
BSNL
Jammu Kashmir Bank
State Bank of India
PUBLIC INTEREST
Passport Department
Income Tax Department
JK CAMPA
JK GAD
IT Education
Web Site Design Services
EDUCATION
Jammu University
Jammu University Results
JKBOSE
Kashmir University
IGNOU Jammu Center
SMVDU